FDA adds rare vision-loss warning to popular GLP-1 drugs
The FDA is adding a new warning to all GLP-1 drugs, including Ozempic and Wegovy, about a rare risk of vision loss from non-arteritic anterior ischemic optic neuropathy. The labeling change follows studies and reports linking the condition to GLP-1 treatments, though the underlying cause remains unclear. The agency notes that cases have been reported in its drug-injury database and through research, prompting heightened attention for patients experiencing visual symptoms. Regulators emphasize ongoing monitoring and advise patients to seek medical care promptly if vision changes occur, with decisions likely guiding future labeling updates and safety communications.
Dive Deeper:
Popular GLP-1 therapies such as Ozempic, Wegovy, Zepbound and Mounjaro are the focus of a newly added FDA warning about a rare, potentially permanent form of vision loss caused by non-arteritic anterior ischemic optic neuropathy.
The warning covers all drugs in the GLP-1 class, which are used to treat obesity, diabetes, and other conditions, reflecting a class-wide safety concern rather than a drug-specific issue.
The FDA linked the risk to decreased blood flow to the optic nerve, a mechanism not yet fully understood, and began its detailed review after a 2024 medical paper suggested a connection with semaglutide.
An FDA analysis across more than 125 clinical trials indicated the event occurs in roughly 6 per 100,000 patients treated for at least a year, compared with less than 4 per 100,000 on placebo or other glucose-lowering therapies.
In addition to trial data, the agency noted reports from its adverse-event database, underscoring the importance of vigilance for visual symptoms among patients on GLP-1 medications.
Symptoms include blurred vision, blind spots, and color distortions; patients are urged to consult a healthcare professional immediately if such signs arise.
The FDA’s action signals ongoing pharmacovigilance and could influence future labeling, safety communications, and monitoring requirements for the GLP-1 drug class.